Madrigal Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Madrigal Pharmaceuticals han disminuido a una tasa media anual de -31.7%, mientras que en la industria Biotechs los beneficios crecieron en un 15.5% anualmente.

Información clave

-31.7%

Tasa de crecimiento de los beneficios

-27.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-52.2%
Margen neto	n/a
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Jun 09

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Apr 24

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow

Nov 17

Madrigal Pharmaceuticals EPS misses by $0.40

Nov 05

Desglose de ingresos y gastos

Cómo gana y gasta dinero Madrigal Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:MDGL Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	-444	173	281
31 Dec 23	-374	108	272
30 Sep 23	-347	76	272
30 Jun 23	-330	61	270
31 Mar 23	-315	55	260
31 Dec 22	-295	48	245
30 Sep 22	-274	45	228
30 Jun 22	-256	41	214
31 Mar 22	-247	40	207
31 Dec 21	-242	37	205
30 Sep 21	-236	32	206
30 Jun 21	-231	29	204
31 Mar 21	-219	24	197
31 Dec 20	-202	22	185
30 Sep 20	-171	21	156
30 Jun 20	-134	20	122
31 Mar 20	-105	22	93
31 Dec 19	-84	23	72
30 Sep 19	-68	23	56
30 Jun 19	-55	24	43
31 Mar 19	-42	19	33
31 Dec 18	-33	15	25
30 Sep 18	-30	12	23
30 Jun 18	-30	9	24
31 Mar 18	-32	8	25
31 Dec 17	-31	8	24
30 Sep 17	-30	7	23
30 Jun 17	-36	9	25
31 Mar 17	-31	8	20
31 Dec 16	-26	7	16
30 Sep 16	-21	5	11
30 Jun 16	-8	1	4
31 Mar 16	-7	1	3
31 Dec 15	-7	1	2

Ingresos de calidad: MDGL actualmente no es rentable.

Margen de beneficios creciente: MDGL actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: MDGL no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 31.7% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de MDGL en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: MDGL no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: MDGL tiene una rentabilidad financiera negativa (-52.22%), ya que actualmente no es rentable.

Madrigal Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Recent updates

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Madrigal: Powerful Catalyst Approaching

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

Madrigal Pharmaceuticals: Leading The NASH Innovation

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

New 90-day low: US$110

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow